dacarbazine has been researched along with oblimersen in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, D | 1 |
| Barvaux, VA; Gillum, AM; Lorigan, P; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M | 1 |
| Buzaid, AC | 1 |
| Piro, LD | 1 |
| Benimetskaya, L; Miller, P; Stein, CA | 1 |
| Bedikian, AY; Conry, R; DeConti, R; Gore, M; Haluska, FG; Hersey, P; Hersh, EM; Kirkwood, JM; Millward, M; Pavlick, AC; Pehamberger, H; Trefzer, U | 1 |
| Ascierto, PA; Casula, M; Cossu, A; Palmieri, G; Tanda, F | 1 |
| Stein, CA | 1 |
| Agarwala, SS; Bedikian, AY; Eggermont, AM; Gilles, E; Itri, LM; Kay, R; Keilholz, U; Stein, CA; Suciu, S; Wu, J | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Bedikian, AY; Conry, R; Garbe, C; Grob, JJ; Lebbe, C | 1 |
2 review(s) available for dacarbazine and oblimersen
| Article | Year |
|---|---|
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Temozolomide; Thionucleotides; Treatment Outcome | 2004 |
Apoptosis, Bcl-2 antisense, and cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Genes, bcl-2; Humans; Melanoma; Neoplasms; Oligonucleotides, Antisense; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Randomized Controlled Trials as Topic; Thionucleotides; Transplantation, Heterologous | 2004 |
4 trial(s) available for dacarbazine and oblimersen
| Article | Year |
|---|---|
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2006 |
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Melanoma; Prognosis; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2009 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
5 other study(ies) available for dacarbazine and oblimersen
| Article | Year |
|---|---|
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Repair; Dose-Response Relationship, Drug; Female; Humans; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotides; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Tetrazolium Salts; Thiazoles; Thionucleotides; Time Factors; Up-Regulation | 2004 |
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides | 2005 |
Molecular classification of patients with malignant melanoma for new therapeutic strategies.
Topics: Combined Modality Therapy; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Skin Neoplasms; Thionucleotides | 2007 |
Genasense: it ain't over till the fat lady sings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Approval; Humans; Melanoma; Oligonucleotides, Antisense; Randomized Controlled Trials as Topic; Skin Neoplasms; Thionucleotides; United States; United States Food and Drug Administration | 2007 |